333 related articles for article (PubMed ID: 16423491)
21. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
Nasa P; Juneja D; Singh O; Dang R; Singh A
Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lautenbach E; Strom BL; Bilker WB; Patel JB; Edelstein PH; Fishman NO
Clin Infect Dis; 2001 Oct; 33(8):1288-94. PubMed ID: 11565067
[TBL] [Abstract][Full Text] [Related]
23. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
[TBL] [Abstract][Full Text] [Related]
24. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
Lee SY; Kuti JL; Nicolau DP
J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
[TBL] [Abstract][Full Text] [Related]
25. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China.
Hu B; Ye H; Xu Y; Ni Y; Hu Y; Yu Y; Huang Z; Ma L
Curr Med Res Opin; 2010 Jun; 26(6):1443-9. PubMed ID: 20394469
[TBL] [Abstract][Full Text] [Related]
26. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
[TBL] [Abstract][Full Text] [Related]
27. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
28. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Kang CI; Song JH; Chung DR; Peck KR; Ko KS; Yeom JS; Ki HK; Son JS; Lee SS; Kim YS; Jung SI; Kim SW; Chang HH; Ryu SY; Kwon KT; Lee H; Moon C; Shin SY;
Int J Antimicrob Agents; 2010 Sep; 36(3):284-7. PubMed ID: 20580534
[TBL] [Abstract][Full Text] [Related]
29. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
Bell JM; Chitsaz M; Turnidge JD; Barton M; Walters LJ; Jones RN
J Clin Microbiol; 2007 May; 45(5):1478-82. PubMed ID: 17344367
[TBL] [Abstract][Full Text] [Related]
31. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
[TBL] [Abstract][Full Text] [Related]
32. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
[TBL] [Abstract][Full Text] [Related]
33. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
34. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections.
Yang YS; Ku CH; Lin JC; Shang ST; Chiu CH; Yeh KM; Lin CC; Chang FY
J Microbiol Immunol Infect; 2010 Jun; 43(3):194-9. PubMed ID: 21291846
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae acquisition in a neonatal intensive care unit.
Shakil S; Ali SZ; Akram M; Ali SM; Khan AU
J Trop Pediatr; 2010 Apr; 56(2):90-6. PubMed ID: 19608665
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
[TBL] [Abstract][Full Text] [Related]
37. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.
Wener KM; Schechner V; Gold HS; Wright SB; Carmeli Y
Antimicrob Agents Chemother; 2010 May; 54(5):2010-6. PubMed ID: 20211888
[TBL] [Abstract][Full Text] [Related]
38. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
Romero L; López L; Rodríguez-Baño J; Ramón Hernández J; Martínez-Martínez L; Pascual A
Clin Microbiol Infect; 2005 Aug; 11(8):625-31. PubMed ID: 16008614
[TBL] [Abstract][Full Text] [Related]
39. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Labombardi VJ; Rojtman A; Tran K
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
